LENZ Therapeutics, Inc.
Business
LENZ Therapeutics is a commercial pharmaceutical company focused on developing and commercializing innovative therapies to improve vision. The company's lead product is VIZZ (aceclidine ophthalmic solution), FDA-approved as the first and only aceclidine-based eye drop for treating presbyopia, which impacts a substantial portion of the global population. VIZZ is commercialized in the U.S. through direct sales to eye care professionals and consumers via retail pharmacies and e-pharmacy partners, with international partnerships established for Greater China, South Korea, Southeast Asia, Canada, and the Middle East.
Summary from 10-K filed 2026-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 19 | 0 | — | — | — | |
| Cost of sales | 418,000 | 0 | — | — | — | |
| Selling, general and administrative | 91 | 29 | 13 | — | — | |
| Research and development | 19 | 30 | 60 | 73 | 38 | |
| Total operating expenses | 110 | 59 | — | — | — | |
| Loss from operations | −91 | −59 | −72 | −106 | −60 | |
| Other (expense) income | −243,000 | 289,000 | 93,000 | 5 | 24,000 | |
| Interest income | 10 | 9 | 2 | — | — | |
| Total other income, net | 10 | 9 | 2 | 5 | −10 | |
| Net loss before income taxes | −82 | −50 | −70 | — | — | |
| Income tax expense | 502,000 | 1,000 | −179,000 | — | — | |
| Net loss | −82 | −50 | −70 | −101 | −71 | |
| Unrealized gain on marketable securities | 46,000 | 190,000 | 6,000 | −1 | 0 | |
| Comprehensive loss | −82 | −50 | −70 | — | — | |
| Net loss per share - basic (in dollars per share) | −2.85 | −2.34 | −35.71 | −1.84 | −2.45 | |
| Net loss per share - diluted (in dollars per share) | −2.85 | −2.34 | −35.71 | −1.84 | −2.45 | |
| Weighted-average common shares outstanding, basic (in shares) | 29 | 21 | 2 | 55 | 29 | |
| Weighted-average common shares outstanding, diluted (in shares) | 29 | 21 | 2 | 55 | 29 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 25 | 20 | 35 | 48 | 377 | |
| Marketable securities | 267 | 189 | 31 | — | — | |
| Accounts receivable, net | 329,000 | 0 | — | — | — | |
| Inventory | 3 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 6 | 3 | 1 | 7 | 5 | |
| Restricted cash | 0 | 114,000 | 0 | — | 2 | |
| Total current assets | 301 | 212 | 67 | 275 | 382 | |
| Property and equipment, net | 1 | 651,000 | 54,000 | 23 | 7 | |
| Operating lease right-of-use asset | 734,000 | 1 | 318,000 | 6 | 12 | |
| Other assets | 3 | 1 | 21,000 | 1 | 454,000 | |
| Total assets | 306 | 215 | 70 | 322 | 402 | |
| Accounts payable | 4 | 4 | 6 | 3 | 2 | |
| Accrued liabilities | 17 | 6 | 13 | — | — | |
| Total current liabilities | 21 | 10 | 19 | 13 | 12 | |
| Operating lease liability, net | 350,000 | 814,000 | 192,000 | 2 | 6 | |
| Total liabilities | 22 | 11 | 20 | 26 | 18 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issues and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, par value of $0.00001 per share; 300,000,000 shares authorized at December 31, 2025 and 2024; 31,344,782 and 27,531,490 shares issued at December 31, 2025 and 2024, respectively; and 31,344,782 and 27,518,439 shares outstanding at December 31, 2025 and 2024, respectively | 1,000 | 1,000 | 10,000 | 1,000 | 1,000 | |
| Additional paid-in capital | 511 | 349 | 3 | 540 | 525 | |
| Accumulated deficit | −227 | −145 | −95 | −242 | −141 | |
| Accumulated other comprehensive income | 242,000 | 196,000 | 6,000 | −1 | 0 | |
| Total stockholders equity | 284 | 204 | −93 | −24 | 384 | |
| Total liabilities and stockholders equity | 306 | 215 | 70 | 322 | 402 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 287,000 | 58,000 | 15,000 | — | — | |
| Loss on disposal of property and equipment | 0 | 16,000 | 0 | — | — | |
| Loss on impairment of operating right-of-use assets and related property and equipment | 82,000 | 0 | — | — | — | |
| Accretion of discounts and amortization of premiums on marketable securities, net | −3 | −4 | −1 | −2 | 0 | |
| Loss (gain) on long-term investments, net | 197,000 | −1 | — | — | — | |
| Change in fair value of preferred stock warrants | 0 | 1 | −123,000 | — | — | |
| Share-based compensation expense | 13 | 6 | 1 | 14 | 8 | |
| Accounts receivable, net | −329,000 | 0 | — | — | — | |
| Inventory | −4 | 0 | — | — | — | |
| Prepaid expenses and other current assets | −3 | 25,000 | 761,000 | −3 | −4 | |
| Accounts payable | −90,000 | −4 | 856,000 | 194,000 | 2 | |
| Accrued liabilities | 11 | −7 | 8 | — | — | |
| Other assets | −1,000 | −41,000 | 10,000 | — | — | |
| Net cash used in operating activities | −69 | −59 | −60 | −88 | −53 | |
| Purchases of marketable securities | −281 | −242 | −52 | — | — | |
| Proceeds from maturities of marketable securities | 206 | 88 | 23 | — | — | |
| Purchases of property and equipment | −827,000 | −468,000 | −30,000 | −7 | −6 | |
| Net cash used in investing activities | −76 | −154 | −30 | −242 | −6 | |
| Proceeds from exercises of stock options | 1 | 4 | 203,000 | 20,000 | 28,000 | |
| Proceeds from issuance of common stock under employee stock purchase plan | 873,000 | 0 | 157,000 | 656,000 | 306,000 | |
| Cash, cash equivalents, and restricted cash acquired in connection with the Merger | 0 | 118 | 0 | — | — | |
| Merger transaction costs | 0 | −2 | 0 | — | — | |
| Net cash provided by financing activities | 150 | 199 | 81 | 597,000 | 417 | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 5 | −15 | −9 | −329 | 359 | |
| Reclassification of warrant liability to equity | 0 | 2 | 0 | — | — | |
| Prepaid expenses and other current assets assumed in the Merger | 0 | 1 | 0 | — | — | |
| Accounts payable and accrued liabilities assumed in the Merger | 0 | 3 | 0 | — | — | |
| Right-of-use assets assumed in the Merger in exchange for operating lease liabilities | 0 | 74,000 | 0 | — | — | |
| Right-of-use assets obtained in exchange for operating lease liabilities | 0 | 1 | 190,000 | — | — | |
| Property and equipment included in accounts payable and accrued expenses | 0 | 203,000 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is LENZ Therapeutics, Inc.'s CIK number?
LENZ Therapeutics, Inc.'s SEC CIK number is 0001815776 (1815776). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find LENZ Therapeutics, Inc.'s SEC filings?
All of LENZ Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did LENZ Therapeutics, Inc. last report earnings?
LENZ Therapeutics, Inc. (LENZ) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001815776-26-000035). This is LENZ Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is LENZ Therapeutics, Inc.'s most recent earnings 8-K?
LENZ Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001815776-26-000035. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View LENZ Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →